Aducanumab (BIIB037) is a human mAb (monoclonal antibody) that was studied for the treatment of Alzheimer's disease. It was developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer. The antibody targets aggregated forms of β-amyloid found in the brains of people with Alzheimer’s disease, in the hopes of reducing its buildup. Biogen halted development of the drug in March 2019 after preliminary data from two phase III trials suggested it would not meet the primary endpoint.

纯度：≥98%

CAS：1384260-65-4